BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25355401)

  • 1. Development of a communication protocol for telephone disclosure of genetic test results for cancer predisposition.
    Patrick-Miller LJ; Egleston BL; Fetzer D; Forman A; Bealin L; Rybak C; Peterson C; Corbman M; Albarracin J; Stevens E; Daly MB; Bradbury AR
    JMIR Res Protoc; 2014 Oct; 3(4):e49. PubMed ID: 25355401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results.
    Patrick-Miller L; Egleston BL; Daly M; Stevens E; Fetzer D; Forman A; Bealin L; Rybak C; Peterson C; Corbman M; Bradbury AR
    Patient Educ Couns; 2013 Dec; 93(3):413-9. PubMed ID: 24075727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic counselor opinions of, and experiences with telephone communication of BRCA1/2 test results.
    Bradbury AR; Patrick-Miller L; Fetzer D; Egleston B; Cummings SA; Forman A; Bealin L; Peterson C; Corbman M; O'Connell J; Daly MB
    Clin Genet; 2011 Feb; 79(2):125-31. PubMed ID: 21039431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in communication of genetic risk for hereditary breast cancer.
    Mackenzie A; Patrick-Miller L; Bradbury AR
    Breast J; 2009; 15 Suppl 1():S25-32. PubMed ID: 19775327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study.
    Beri N; Patrick-Miller LJ; Egleston BL; Hall MJ; Domchek SM; Daly MB; Ganschow P; Grana G; Olopade OI; Fetzer D; Brandt A; Chambers R; Clark DF; Forman A; Gaber R; Gulden C; Horte J; Long J; Lucas T; Madaan S; Mattie K; McKenna D; Montgomery S; Nielsen S; Powers J; Rainey K; Rybak C; Savage M; Seelaus C; Stoll J; Stopfer JE; Yao XS; Bradbury AR
    Clin Genet; 2019 Feb; 95(2):293-301. PubMed ID: 30417332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient satisfaction of BRCA1/2 genetic testing by women at high risk for breast cancer participating in a prevention trial.
    Klemp JR; O'Dea A; Chamberlain C; Fabian CJ
    Fam Cancer; 2005; 4(4):279-84. PubMed ID: 16341803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
    Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
    J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of mailed results versus telephone disclosure of normal cancer genetic test results in a low-risk underserved population.
    Gilmore MJ; Leo MC; Amendola LM; Goddard KAB; Ezzell Hunter J; Joseph G; Kauffman TL; Rolf B; Shuster E; Zepp JM; Wilfond BS; Biesecker BB
    Transl Behav Med; 2024 Jun; 14(7):377-385. PubMed ID: 38190737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell.
    Patenaude AF; Dorval M; DiGianni LS; Schneider KA; Chittenden A; Garber JE
    J Clin Oncol; 2006 Feb; 24(4):700-6. PubMed ID: 16446344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
    Flores KG; Steffen LE; McLouth CJ; Vicuña BE; Gammon A; Kohlmann W; Vigil L; Dayao ZR; Royce ME; Kinney AY
    J Genet Couns; 2017 Jun; 26(3):480-490. PubMed ID: 27496122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementing an Internet-Delivered Skin Cancer Genetic Testing Intervention to Improve Sun Protection Behavior in a Diverse Population: Protocol for a Randomized Controlled Trial.
    Hay JL; Berwick M; Zielaskowski K; White KA; Rodríguez VM; Robers E; Guest DD; Sussman A; Talamantes Y; Schwartz MR; Greb J; Bigney J; Kaphingst KA; Hunley K; Buller DB
    JMIR Res Protoc; 2017 Apr; 6(4):e52. PubMed ID: 28442450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The phases of disclosing BRCA1/2 genetic information to offspring.
    Clarke S; Butler K; Esplen MJ
    Psychooncology; 2008 Aug; 17(8):797-803. PubMed ID: 18646247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
    J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    Rayes N; Bowen DJ; Coffin T; Nebgen D; Peterson C; Munsell MF; Gavin K; Lechner R; Crase J; Polinsky D; Romero I; Blank SV; Levine DA; Norquist BM; Swisher EM; Lu KH
    BMC Cancer; 2019 Jul; 19(1):648. PubMed ID: 31266460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of phone versus in-person BRCA1/2 predisposition genetic test result disclosure counseling.
    Jenkins J; Calzone KA; Dimond E; Liewehr DJ; Steinberg SM; Jourkiv O; Klein P; Soballe PW; Prindiville SA; Kirsch IR
    Genet Med; 2007 Aug; 9(8):487-95. PubMed ID: 17700386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and early-stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient-driven approach.
    Pollard S; Weymann D; Loewen R; Nuk J; Sun S; Schrader KA; Hessels C; Regier DA
    Health Expect; 2023 Apr; 26(2):774-784. PubMed ID: 36660874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results.
    Bradbury AR; Patrick-Miller LJ; Egleston BL; Hall MJ; Domchek SM; Daly MB; Ganschow P; Grana G; Olopade OI; Fetzer D; Brandt A; Chambers R; Clark DF; Forman A; Gaber R; Gulden C; Horte J; Long JM; Lucas T; Madaan S; Mattie K; McKenna D; Montgomery S; Nielsen S; Powers J; Rainey K; Rybak C; Savage M; Seelaus C; Stoll J; Stopfer JE; Yao XS
    J Natl Cancer Inst; 2018 Sep; 110(9):985-993. PubMed ID: 29490071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanding access to BRCA1/2 genetic counseling with telephone delivery: a cluster randomized trial.
    Kinney AY; Butler KM; Schwartz MD; Mandelblatt JS; Boucher KM; Pappas LM; Gammon A; Kohlmann W; Edwards SL; Stroup AM; Buys SS; Flores KG; Campo RA
    J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25376862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of individuals opting for BRCA1/2 or HNPCC genetic susceptibility testing with regard to coping, illness perceptions, illness experiences, family system characteristics and hereditary cancer distress.
    van Oostrom I; Meijers-Heijboer H; Duivenvoorden HJ; Bröcker-Vriends AH; van Asperen CJ; Sijmons RH; Seynaeve C; Van Gool AR; Klijn JG; Tibben A
    Patient Educ Couns; 2007 Jan; 65(1):58-68. PubMed ID: 16872788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.